24/7 Market News Snapshot 14 July, 2025 – BiomX Inc. (NYSE:PHGE)

July 14, 2025

DENVER, Colo., 14 July, 2025 (www.247marketnews.com) – (NYSE:PHGE) are discussed in this article.
BiomX Inc. has recently made headlines with its stock witnessing a remarkable surge of 84.82% in pre-market trading, reaching $0.767 from a previous close of $0.415. This rally, marked by a volume of 18.78 million shares, reflects heightened investor confidence in the company’s promising therapeutic innovations. Analysts observe significant upward momentum that may suggest a potential for further gains in the biotech sector, warranting close attention from investors as market activities evolve.

In conjunction with this financial momentum, BiomX has successfully initiated patient dosing in its Phase 2b clinical trial for BX004, a novel candidate aimed at treating chronic pulmonary infections linked to Pseudomonas aeruginosa in cystic fibrosis patients. The anticipated topline results are expected in the first quarter of 2026, building on the encouraging outcomes from the prior Phase 1b/2a study, where complete bacterial clearance was observed in 14.3% of participants after just ten days of treatment. These initial results have generated considerable enthusiasm among stakeholders and underscore the potential of BX004 as an alternative solution for patients facing long-standing infections resistant to traditional treatments.

Jonathan Solomon, the Chief Executive Officer of BiomX, expressed optimism about this milestone, emphasizing the urgent need for innovative options in cystic fibrosis treatment and the favorable groundwork laid by earlier study results. The ongoing Phase 2b trial will include around 60 patients who will be randomized to receive either BX004 or a placebo, with treatment administered twice daily over eight weeks. The trial aims to evaluate key efficacy indicators, such as bacterial load reduction and improvements in lung function.

With FDA Fast Track and Orphan Drug designations already secured, BiomX is poised to potentially accelerate the development of BX004. Anticipated feedback from the FDA in late 2025 may provide further strategic insights to facilitate regulatory pathways, enhancing the possibilities for this groundbreaking therapeutic option tailored to combat antibiotic-resistant infections.

Related news for (PHGE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.